Abstract: Hedgehog (Hh) proteins are prototypical morphogens known to regulate epithelial/mesenchymal interactions during embryonic development. In addition to its pivotal role in embryogenesis, the Hh signaling pathway may be recapitulated in post-natal life in a number of physiological and pathological conditions, including ischemia. This review highlights the involvement of Hh signaling in ischemic tissue regeneration and angiogenesis, with particular attention to the heart, the brain, and the skeletal muscle. Updated information on the potential role of the Hh pathway as a therapeutic target in ischemic condition is also presented.
Introduction
Hedgehog (Hh) signaling was first described in 1980 by Nusslein-Volhard and Wieschaus and was initially addressed as a key mediator of cellular proliferation, differentiation, and migration during organogenesis in invertebrates [1] . The general signaling mechanism for the Hh pathway is conserved from fly to mammal although more and distinct components have been found in mammalian cells [2] . In the early 1990s, three Hh homologs were discovered in vertebrates: Sonic (Shh), Desert (Dhh), and Indian hedgehog (Ihh). Among them, Shh is the most widely expressed during development and the best studied. The initial evidence for the importance of Hh signaling in mammalian development was provided by observations that mutations in Shh cause holoprosencephaly, a developmental disorder that affects midline morphogenesis of the face and nervous system [3] [4] [5] . Although most studies of Hh signaling focus on Shh, the other two ligandsDhh and Ihh -share many of the same downstream signaling components. The Dhh ligand is more abundant in the reproductive organs of both males and females, including Sertoli cells of testes and granulosa cells of ovaries [6, 7] . Consistent with this, male mice lacking Dhh are infertile due to the complete absence of mature sperm [6] . Ihh plays instead an important role in skeletal development, primarily in cortical bone and long bone formation. The most severe manifestation of Ihh deficiency may be seen in children with acrocapitofemoral dysplasia, who have short stature and bone defects [8] .
Canonically, Hh signaling occurs through binding of Hh proteins to the twelvetransmembrane domain receptor Patched (Ptch). Binding of a Hh ligand to Ptch results in Ptch internalization and abolishment of its inhibitory activity on the seven-transmembrane GPCR-like protein Smoothened (Smo). Smo is subsequently phosphorylated at its intracellular C-terminus and undergoes reciprocal translocation to the plasma membrane of non-motile cilia, inhibiting the downstream proteolytic processing of GLI2 and GLI3, leading to the production of full-length activated Gli proteins (GliA). GliA enter the nucleus and stimulate transcription of the ubiquitous Hh target genes, GLI1, PTCH, and HHIP (Hh interacting protein). Signal transmission is then controlled through a complex signaling cascade that results in a balance between activator (GliA) and repressor (GliR) proteins [9] . In addition to this canonical pathway, there are cellular and tissue responses to Hh ligands that are independent of transcriptional changes mediated by the Gli family. These pathways may be important for apoptosis, cell duplication, differentiation, and determination. For instance, it has been reported that Smo modulates actin cytoskeleton-dependent processes, such as fibroblast migration, endothelial cell tubulogenesis, axonal extension, and neurite formation, by mechanisms that exclude Gli-dependent transcription [10] .
It was 2001 when we first reported that the Hedgehog (Hh) signaling pathway has a role in angiogenesis [11] . Before that seminal publication, there were only sparse observations pointing to the possible involvement of Hh in vascularizing certain embryonic tissues. For instance, it was known that hypervascularization of the neuroectoderm occurs upon transgenic overexpression of Shh in the dorsal neural tube [12] , or that Shh-deficient zebrafish has disorganization of endothelial precursors and inability to form the dorsal aorta or axial vein [13] , or that Shh-deficient mice lack proper vascularization of the developing lung [14] . Nowadays, there is substantial evidence that the Hh signaling pathway is an important player in the regulation of angiogenesis in a number of physiological and pathological conditions in post-natal life, with multiple implications in the field of cardiovascular medicine, neurology, and oncology. This review presents an updated summary of our understanding of the Hh signaling pathway in the regulation of angiogenesis, with a specific focus on Hh-mediated effects at the level of the ischemic heart, brain, and skeletal muscle.
Hedgehog in the ischemic skeletal muscle
In the adult vasculature, adventitial cells, endothelial cells, and cells in the medial layer normally express the Hh receptor Ptch, indicating that adult cardiovascular tissues are ready to respond to Hh ligands in post-natal life [11] . One condition that leads to such event, with overexpression of Shh and upregulation of Ptch, is ischemia of the skeletal muscle [15] . In this setting, Shh and Ptch upregulation take place in the same cell type, i.e. interstitial mesenchymal cells within the ischemic area, indicating the presence of an autocrine mechanism. These cells produce vascular endothelial growth factor (VEGF) under ischemic conditions, through a Shhdependent mechanism, as demonstrated by the evidence that VEGF upregulation is reduced in mice treated with a Shh-blocking antibody after induction of ischemia [15] .
The fact that Shh modulates VEGF production in ischemic tissues is one of the fundamental mechanisms through which the Hh pathway regulates angiogenesis. Indeed, we have originally reported that Shh has no direct effect on endothelial cell migration or proliferation [11] . Instead, Shh induces expression of angiogenic cytokines, including all three VEGF-1 isoforms and angiopoietins-1 and -2, from interstitial mesenchymal cells, thus acting as an indirect angiogenic agent [11] . The ability of Shh to induce the production of angiogenic growth factors, including VEGF, HGF, PDGF-BB, and IGF, in interstitial cells and fibroblasts has been later confirmed by other authors [16] [17] [18] [19] . Also, it has been confirmed that Hh ligands are unable to induce Gli-target genes in endothelial cells and that Shh has limited effects on endothelial cell proliferation and migration [20, 21] . There is also the demonstration that Gli3 deficiency in endothelial cells does not affect repair of the ischemic skeletal muscle [22] . On the other hand, it has been reported that Hh proteins have the ability to promote endothelial cell tubulogenesis through a non-canonical Hh pathway that involves Smo, Gi proteins, and Rac1 and results in cytoskeletal rearrangement and formation of actin stress fibers in endothelial cells [20] . Nonetheless, endothelial-specific Smo knockout (eSmoNull) mice have no observable phenotype and display unaltered ability to mount an appropriate angiogenic process in response to hindlimb ischemia [23] . Even Shh-induced corneal angiogenesis is normal in eSmoNull mice [23] . Taken together, these findings highlight the complexity of the Hh pathway and indicate that further studies are needed to fully understand the molecular mechanisms responsible for Hh-regulated angiogenesis.
Some controversies also exist on the identity of the Hh ligand that plays the most important role during ischemia-induced angiogenesis. We have found that hindlimb ischemia results in upregulation of Shh expression, without detectable effect on Ihh and Dhh [15] . However, more recent findings indicate that limb perfusion is significantly impaired in the absence of Dhh, due to the fact that Dhh is important for peripheral nerve survival in the ischemic muscle and the maintenance of the pool of nerve-derived proangiogenic factors [24] . In addition, the rescue of Dhh expression by gene therapy in old mice promotes ischemia-induced angiogenesis [24] .
If, on one hand, it is still not completely clear how Hh regulates angiogenesis, on the other hand it is generally accepted that stimulation of the Hh pathway may help revascularization and repair of ischemic tissues. Indeed, Shh protein, injected intraperitoneally in aged mice, augments blood-flow recovery and limb salvage following operatively induced hind-limb ischemia [11] . Also, intramuscular treatment with a plasmid encoding the Shh human gene (phShh) increases blood flow, capillary density, and arteriole density in old mice in which peripheral circulation of the hindlimb has been disrupted by removal of the common femoral artery, or in which the skeletal muscle has been mechanically injured [25, 26] . Shh gene therapy also enhances vasculogenesis, by increasing the number of circulating bone marrow (BM)-derived endothelial progenitor cells (EPCs) and improving the contribution of these cells to the process of neovascularization [27] . Combined therapy with Shh gene transfer and BM-derived EPCs is more effective than Shh gene therapy alone in an experimental model of peripheral limb ischemia [28] . The importance of the Hh pathway in the pathophysiology of the EPC compartment has been recently further strengthened by the demonstration that Gli1 and Ptch expression are reduced in the EPCs of streptozotocin (STZ)-induced type 1 diabetic mice and that administration of a Shh pathway receptor agonist restores both the number and function of EPCs and increases neovascularization in these mice in response to ischemia [29] . Finally, as mentioned above, there are data supporting a potential therapeutic role also for Dhh in the ischemic skeletal muscle [24] .
A summary of the results of the studies conducted on the ischemic skeletal muscle is presented in Table 1 . 
Hedgehog in the ischemic heart
Hh signaling seems to have a crucial homeostatic role in the adult heart. This has been elegantly demonstrated by Lavine and coll., who have ablated endogenous Hh signaling in murine myocardial and perivascular smooth muscle cells, finding that, in the absence of Hh, there is loss of coronary blood vessels, tissue hypoxia, cardiomyocyte cell death, heart failure, and increased lethality [30] . However, a study by Paulis and coll. has shown that, although Ptch and Smo are expressed in adult cardiomyocytes, inhibition of the endogenous Hh does not result in significant electrocardiographic (ECG) changes, suggesting that active Hh signaling is not important in the adult heart [31] . This apparent contradiction between the two studies might depend on the fact that, in the latter study, inhibition of the Hh pathway was achieved by infusing the Hh antagonist cyclopamine for only 6 hours before ECG analysis, while in the study of Lavine and coll. the inhibition of the pathway lasted several days and was obtained by ablating Smo in specific cell types.
During myocardial ischemia, there is a strong upregulation of Shh and Ptch in the adult mouse heart [32] [33] [34] . Xiao and coll. have reported that, in streptozotocin-induced type 1 diabetic mice, myocardial expression of Shh, Ptch, and Gli1 is significantly decreased, and this is accompanied by cardiac dysfunction [32] . In these mice, treatment with a Shh pathway agonist significantly increases Ptch and Gli1 proteins, enhances capillary density, reduces the percentage of myocardial infarction size, and ameliorates cardiac function. These findings indicate that in type 1 diabetic mice the myocardial Shh pathway is impaired and that strategies aimed at stimulating the Shh pathway may be beneficial for improving cardiac dysfunction.
Taken together, these results suggest that Hh signaling has a protective role in response to cardiac ischemia. Based on this, several experimental studies have tested the possibility to enhance angiogenesis and improve heart function after myocardial ischemia, by acting on the Hh pathway. Our group has used intramyocardial gene transfer of naked DNA encoding human Shh (phShh) to enhance neovascularization, reduce fibrosis, and preserve left ventricular function in rabbit and pig models of acute and chronic myocardial ischemia [33] . Ahmed and coll. have overexpressed Shh in rat mesenchymal stem cells (MSCs) [35] . The consequence has been increased expression of angiogenic and pro-survival growth factors in transfected cells, along with improved ability to migrate and form tubes in vitro. When injected in the ischemic myocardium, Shh-overexpressing MSCs lead to increased density of functionally competent blood vessels and preserve function of the left ventricle. Guo and coll. have overexpressed Shh in cardiac microvascular endothelial cells (CMECs) isolated from rat heart tissues [36] . This has resulted in increased CMEC viability and decreased apoptosis, along with increased production of angiogenic factors, including VEGF, FGF and angiopoietins. In a rat model of ischemia-reperfusion, stimulation of Shh pathway prior to reperfusion has reduced both infarct size and subsequent arrhythmias by preventing ventricular repolarization abnormalities [31] . This is an interesting cardio-protective effect of Shh acting directly on cardiomyocytes.
The angiogenic effects of Shh in the ischemic heart appear to be mediated by the canonical Glidependent pathway. Indeed, surgically induced myocardial infarction results in reduced capillary density and left ventricular ejection fraction in Gli3-haploinsufficient (Gli3(+/-)) mice, compared to wild-type mice [21] . Gli3-deficient mice also display reduced capillary density after induction of hindlimb ischemia and impaired angiogenic response to VEGF in the corneal angiogenesis model [21] . Also, a microarray analysis of gene expression changes elicited by Shh and sensitive to a Smo inhibitor has led to the identification of a subset of 37 cardiomyocyte-specific genes regulated by Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 1 August 2018 doi:10.20944/preprints201808.0027.v1
Shh, including some in the PKA and purinergic signaling pathways [37] . In addition, neonatal rat ventricular cardiomyocytes infected with an adenovirus encoding GiCT, a peptide that impairs receptor-Gi protein coupling, showed reduced activation of Hh targets. In vitro data were confirmed in transgenic mice with cardiomyocyte-inducible GiCT expression [37] . Transgenic GiCT mice showed specific reduction of Gli1 expression in the heart under basal conditions and failed to upregulate the Hh pathway upon ischemia and reperfusion injury [37] . This study characterizes the transcriptional response of cardiomyocytes to Shh and establishes a critical role for Smo coupling to Gi in Hh signaling in the normal and ischemic myocardium. The results of the studies conducted on the ischemic heart are summarized in Table 2 . 
Hedgehog in the ischemic brain
A number of data support the concept that Hh signaling is an important regulator of neurogenesis and angiogenesis in the adult brain. For instance, it is known that Shh is required for the maintenance of neural progenitor cells (NPCs) in the adult hippocampus and regulates the proliferation of NPCs after ischemia/hypoxia [38] . Middle cerebral artery occlusion is associated with increased mRNA encoding both Shh and its transcription factor Gli1, already a few hours after induction of brain ischemia [38] . By employing a co-culture system of brain microvascular endothelial cells (BMECs) and astrocytes, incubated under oxygen-glucose deprivation (OGD) condition, it has been demonstrated that Shh is secreted by activated astrocytes and promotes proliferation, migration, and tube formation of BMECs [39] . In this assay, proliferation, migration, and tube formation of BMECs may be suppressed by silencing the Ras homolog gene family member A (RhoA) and blocking Rho-dependent kinase (ROCK) [39] . Not only ODG, but also oxidative stress has been shown to have the ability of activating the Shh pathway in cultured cortical neurons [40] . In this setting, activation of endogenous Shh signaling protects neurons from H₂O₂-induced apoptosis and increases cell viability. In addition, in H₂O₂-treated neurons, exogenous Shh increases the activities of Superoxide dismutase (SOD) and Glutathione peroxidase (GSH-PX) and decreases production of Malondialdehyde (MDA). It also promotes expression of the anti-apoptotic gene Bcl-2 and inhibits expression of pro-apoptotic gene Bax. Activation of Shh signal also leads to upregulated expression of both neurotrophic and vascular factors, such as VEGF and brain-derived neurotrophic factor (BDNF) [40, 41] .
The importance of endogenous Shh upregulation in the ischemic brain is demonstrated by the fact that, upon induction of experimental cerebral ischemia, inhibition of the Shh pathway results in increased infarct volume, brain water content, and behavioral deficits [42] . The endogenous Hh pathway appears to be important also for the beneficial effects induced by bone marrow stromal cells (MSCs) on neurologic recovery after middle cerebral artery occlusion in mice [43] . Indeed, treatment with MSCs significantly enhances functional recovery after middle cerebral artery occlusion, concurrent with increases of synaptophysin, synapse density, and myelinated axons along the ischemic boundary zone. However, these benefits are significantly reduced by blockage of the endogenous Shh pathway [43] . Also, the beneficial effects displayed by cerebrolysin -a mixture of neurotrophic peptides -in experimental neurodegenerative diseases and stroke seem to depend on proper activity of the endogenous Hh pathway [44] . Indeed, cerebrolysin significantly increases neural progenitor cell proliferation and differentiation into neurons and myelinating oligodendrocytes in rats subjected to embolic stroke. However, blockage of the Shh signaling pathway with a pharmacological smoothened inhibitor, cyclopamine, abolishes cerebrolysininduced in vitro neurogenesis and oligodendrogenesis. Moreover, profound neurological function improvements were observed in rats treated with cerebrolysin from week 3 to week 5 after stroke onset. However, in vivo inhibition of the Shh pathway with cyclopamine completely reverses the effects of cerebrolysin on functional recovery.
Taken together, these finding suggest a potential role for Shh in the treatments of brain ischemia. Based on that, Chen and coll. have performed intracerebroventricular injections of Shh in rats immediately after permanent middle cerebral artery occlusion [17] . This treatment has reduced infarct volume, led to improved microvascular density and neuron survival in the ischemic boundary zone, and improved neurological scores. These beneficial effects occurred along with enhanced VEGF expression [17] . Stimulation of the Shh pathway appears to be beneficial even if performed not immediately after stroke. Indeed, delayed treatment (1 month after stroke) with a Shh agonist in mice resulted in enhanced functional recovery both in locomotor and cognitive function [45] . Furthermore, using a genetically inducible neural stem cell-specific reporter mouse line (nestin-CreERT2-R26R-YFP), which allows to label and track neural stem cell proliferation, survival, and differentiation in ischemic brain, it was shown that post-stroke treatment with a Shh pathway agonist increases survival of newly born cells derived from both subventricular and subgranular zone and neurons in the ischemic brain [45] . Huang and coll. have tested whether epidural application of the biologically active N-terminal fragment of Shh (Shh-N) may reduce the extent of ischemic brain injury in rats exposed to a 60-min episode of middle cerebral artery occlusion. Shh-N was applied topically, by placing a fibrin glue over the peri-infarct cortex [46] . They found that such treatment substantially reduced infarct volumes after 7 days of reperfusion. It 
Concluding Remarks
Once believed to be important only during embryonic development, the Hh signaling pathway is now recognized as a crucial player in many physiological and pathological conditions in postnatal life. Its role during ischemia-induced angiogenesis and tissue repair has been extensively investigated in the last two decades and seems to be particularly important in organs such as the heart, the brain, and the skeletal muscle. Although the precise molecular and cellular mechanisms underlying Hh-mediated angiogenesis still require to be fully elucidated, there is substantial evidence supporting the concept that the endogenous Hh signaling pathway has the ability to orchestrate multiple aspects of the angiogenic response to ischemia, mainly through the production of angiogenic growth factors from interstitial cells and fibroblasts and the regulation of EPC activity. Nevertheless, there is evidence that many activities of Hh proteins in the ischemic heart and brain occur through direct stimulation of cardiomyocytes and neural cells. Based on the concept that the endogenous Hh pathway is important for efficient angiogenic response to ischemia, several studies have focused on the use of agonists of the Hh pathway to stimulate therapeutic angiogenesis. Successful results have been achieved in experimental models of myocardial infarction, ischemic stroke, and peripheral limb ischemia, but further studies are needed to fully understand the translational significance and potential clinical implications of these findings.
